Welcome!

News Feed Item

Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth

NEW YORK, Nov. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth

http://www.reportlinker.com/p01041701/Parenteral-Nutrition-Market-to-201...

Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth

Summary

EuropeGermanyFranceItalySpainJapan

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The PN market is rapidly growing with the increasing incidence of diseases such as cancer, AIDS and GI disorders including short bowel syndrome, ischemic bowel disease, pseudo obstruction and Crohn's disease. The other major factor driving growth of the PN market is an increase in the elderly population in the developed countries. In 2011, the global PN market was estimated to be worth $2.9 billion, representing a CAGR of 6.3% between 2004 and 2011. The US market, with sales worth $1,476m in 2011, accounted for 50.7% of the total PN market. The market in the top five countries in Europe was estimated to be $1,275m, the second largest PN market, and to have grown at a CAGR of 5.4% between 2004 and 2011. The PN market in Japan registered a share of 5.4% of the total PN market, accounting for $157m sales value in 2011.

By 2018, the PN market is forecast to be worth $4,861m, representing a CAGR of 7.6% between 2011 and 2018. The US is expected to remain the largest segment in the PN market with $2,492m of sales in 2018. The PN market in the top five countries in Europe will be the second largest segment with $2,104m in revenues in 2018. Japan, which was the smallest segment in 2011, is expected to register sales value of $265m in 2018, indicating a CAGR of 7.8% between 2011 and 2018. The PN market M&A landscape demonstrated a fairly moderate level of activity between 2004 and 2010, with seven major acquisition deals signed during the time period.

Scope

- Annualized market data for the PN market from 2004 to 2011, forecast forward to 2018.- Analysis of the PN market in the leading geographies of the world, which include the US, the top five countries in Europe (the UK, Germany, France, Italy, Spain) and Japan. - Market segmentation of the PN market which includes the amino acid, lipids, carbohydrates and additives market in the leading geographies.- Key drivers and barriers that have a significant impact on the market. - Competitive benchmarking of the leading companies. The key companies studied in this report are Baxter, B. Braun, Fresenius Kabi, Hospira, Otsuka Pharmaceutical Factory, Terumo Corporation and Ajinomoto.- Key M&A activities, licensing agreements that have taken place between 2004 and 2011 in the global PN market.

Reasons to buy

- Develop market-entry and market expansion strategies by identifying the leading geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class products with more efficiency and better safety.- Develop key strategic initiatives by understanding the key focus areas of leading companies. - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Parenteral Nutrition Market to 2018 - Introduction 93 Parenteral Nutrition Market to 2018 - Overview 103.1 Clinical Nutrition 103.1.1 Enteral Nutrition 113.1.2 Parenteral Nutrition 114 Parenteral Nutrition Market to 2018 - Market Characterization and Forecasts 154.1 Revenue Forecasts 154.2 Parenteral Nutrition Market Drivers 164.2.1 Increase in the Incidence of Diseases such as Cancer, AIDS and GI Disorders that Require Nutrition Support 174.2.2 Increase in the Elderly Population will Drive PN Market Growth 174.2.3 The Home Parenteral Nutrition Sector will Witness Strong Market Growth 174.3 Parenteral Nutrition Market Restraints 174.3.1 Reimbursement Regulations will Hinder Market Growth in the US 174.3.2 Increasing Preference for Enteral Nutrition will Restrain Market Growth 174.3.3 Increasing Preference for Multi-chamber Bags Decreases Cost of Therapy 185 Parenteral Nutrition Market to 2018 - Geographical Landscape 195.1 Revenues by Geographical Segmentation 195.2 The US 215.2.1 Sales Value 215.2.2 Nutrient Market Segmentation 225.2.3 Key Products 225.3 Top Five Countries in Europe 235.3.1 Sales Value 235.3.2 Nutrient Market Segmentation 245.3.3 Key Products 245.4 Japan 255.4.1 Sales Value 255.4.2 Nutrient Market Segmentation 265.4.3 Key Products 266 Parenteral Nutrition Market to 2018 - Nutrient Market Segmentation 276.1 Overview 276.2 Amino Acids Market 286.2.1 Global Sales Value 286.2.2 Sales Value by Geography 286.3 Lipids Market 296.3.1 Global Sales Value 296.3.2 Sales Value by Geography 296.4 Carbohydrates Market 306.4.1 Global Sales Value 306.4.2 Sales Value by Geography 306.5 Additives Market 316.5.1 Global Sales Value 316.5.2 Sales Value by Geography 317 Parenteral Nutrition Market - Marketed Products 327.1 Baxter International Inc. 327.1.1 OLIMEL 327.1.2 Clinimix 337.1.3 ClinOleic 20% 347.1.4 Clinisol 15% 357.2 B. Braun Melsungen AG 367.2.1 NuTRIflex System 367.2.2 Lipofundin 377.2.3 Aminoplasmal 387.2.4 FreAmine III 397.3 Fresenius Kabi AG 407.3.1 Intralipid 407.3.2 SmofKabiven 417.3.3 Dipeptiven 427.3.4 Omegaven 437.4 Hospira, Inc. 447.4.1 Aminosyn 447.4.2 Liposyn 467.5 Otsuka Pharmaceutical Factory Inc. 477.5.1 Elneopa 477.5.2 Neoparen 477.5.3 B-Fluid 487.6 Terumo Corporation 497.6.1 Unicaliq 497.6.2 Fulcaliq 508 Parenteral Nutrition Market to 2018 - Competitive Landscape 518.1 Market Share Analysis: Parenteral Nutrition 518.2 Competitive Profiling 528.2.1 Baxter International Inc. 528.2.2 B. Braun Melsungen AG 548.2.3 Fresenius Kabi AG 568.2.4 Hospira, Inc. 588.2.5 Otsuka Pharmaceutical Factory Inc. 608.2.6 Terumo Corporation 619 Parenteral Nutrition Market to 2018 - Strategic Consolidations 629.1 Overview 629.2 Major Acquisitions in the Parenteral Nutrition Market 639.2.1 Baxter International Completes Acquisition of Prism Pharma for $338m in April 2011 639.2.2 Baxter Acquires Willow Healthcare Services in July 2009 639.2.3 Fresenius Acquires Novartis Nutrition and Nestle Espana in December 2007 639.2.4 Fresenius Kabi Acquires Infusia A.S. in December 2004 639.2.5 Fresenius Kabi Acquires Clinico GmbH in October 2005 639.2.6 Fresenius Kabi Acquires Isotec Nutrition from Alliance Pharmaceuticals in May 2004 639.2.7 Hospira Acquires Clayton Manufacturing Facility from Fresenius Kabi in June 2004 639.3 Major Agreements in the Parenteral Nutrition Market 649.3.1 Baxter Signs Agreement with Hanmi Pharmaceuticals in December 2010 649.3.2 Hospira Signs a Five-year Agreement with Novation in October 2010 649.3.3 B. Braun Signs Agreement with Amerinet Inc in October 2009 649.3.4 B. Braun Signs Agreement with Premier Purchasing Partners in August 2008 649.3.5 Hospira Announces New Contract with Premier Purchasing Partners in August 2008 659.3.6 Hospira Announces New Contract with HealthTrust Purchasing Group in February 2008 659.3.7 Baxter and Novation Sign Two-year Contract Extension in October 2007 659.3.8 Baxter Announces Plans to Form Parenteral Nutrition Joint Venture with Baiyunshan in China in August 2007 659.3.9 B. Braun Signs Agreement with Curlin Medical in March 2006 659.3.10 Fresenius Kabi and Pharmatel Pty Ltd. Formed a Joint Venture in September 2004 6610 Parenteral Nutrition Market to 2018 - Appendix 6710.1 Market Definitions 6710.2 Abbreviations 6710.3 Bibliography 6810.4 Research Methodology 6910.4.1 Coverage 6910.4.2 Secondary Research 6910.4.3 Primary Research 6910.4.4 Section Methodology 7010.4.5 Expert Panel Validation 7010.5 Contact Us 7010.6 Disclaimer 70

1.1 List of Tables

Table 1: Parenteral Nutrition Market, Global, Nutritional Status Assessment, 2011 10Table 2: Parenteral Nutrition Market, The US, A.S.P.E.N. Guidelines for Parenteral Nutrition, 2004 13Table 3: Parenteral Nutrition Market, Global, Revenues ($m), 2004-2011 15Table 4: Parenteral Nutrition Market, Global, Revenue Forecasts ($m), 2011-2018 15Table 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 19Table 6: Parenteral Nutrition Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 20Table 7: Parenteral Nutrition Market, The US, Revenues ($m), 2004-2011 21Table 8: Parenteral Nutrition Market, The US, Revenue Forecasts ($m), 2011-2018 21Table 9: Parenteral Nutrition Market, Top Five Countries of Europe, Revenues ($m), 2004-2011 23Table 10: Parenteral Nutrition Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 23Table 11: Parenteral Nutrition Market, Japan, Revenues ($m), 2004-2011 25Table 12: Parenteral Nutrition Market, Japan, Revenue Forecasts ($m), 2011-2018 25Table 13: Parenteral Nutrition Market, Amino Acids Revenue by Geographical Segmentation ($m), 2011 28Table 14: Parenteral Nutrition Market, Lipids Revenue by Geographical Segmentation ($m), 2011 29Table 15: Parenteral Nutrition Market, Carbohydrates Revenue by Geographical Segmentation ($m), 2011 30Table 16: Parenteral Nutrition Market, Additives Revenue by Geographical Segmentation ($m), 2011 31Table 17: Parenteral Nutrition Market, Global, Product Composition - Lipofundin, 2012 37Table 18: Parenteral Nutrition Market, Global, Product Composition - Aminoplasmal, 2012 38Table 19: Parenteral Nutrition Market, Global, Product Composition - Aminosyn, 2012 45Table 20: Parenteral Nutrition Market, Global, Strategic Consolidations Overview, 2012 62

1.2 List of Figures

Figure 1: Parenteral Nutrition Market, Global, Nutritional Support Algorithm 11Figure 2: Parenteral Nutrition Market, Global, Nutrition Requirements for TPN, 2012 12Figure 3: Parenteral Nutrition Market, Global, Revenues ($m), 2004-2018 15Figure 4: Parenteral Nutrition Market, Global, Drivers and Barriers, 2012 16Figure 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), 2004-2018 19Figure 6: Parenteral Nutrition Market, The US, Historic Revenue and Forecasts ($m), 2004-2018 21Figure 7: Parenteral Nutrition Market, The US, Key Products, 2012 22Figure 8: Parenteral Nutrition Market, Top Five Countries of Europe, Historic Revenue and Forecasts ($m), 2004-2018 23Figure 9: Parenteral Nutrition Market, Top Five Countries in Europe, Key Products, 2011 24Figure 10: Parenteral Nutrition Market, Japan, Revenue Forecasts ($m), 2004-2018 25Figure 11: Parenteral Nutrition Market, Japan, Key Products, 2011 26Figure 12: Parenteral Nutrition Market, Global, Nutrient Market Segmentation (%), 2011 27Figure 13: Parenteral Nutrition Market, Amino Acids Revenue by Geographical Segmentation ($m), 2011 28Figure 14: Parenteral Nutrition Market, Lipids Revenue by Geographical Segmentation ($m), 2011 29Figure 15: Parenteral Nutrition Market, Carbohydrates Revenue by Geographical Segmentation ($m), 2011 30Figure 16: Parenteral Nutrition Market, Additives Revenue by Geographical Segmentation ($m), 2011 31Figure 17: Parenteral Nutrition Market, Global, Product Profile - OLIMEL, 2012 32Figure 18: Parenteral Nutrition Market, Global, Product Profile - Clinimix, 2012 33Figure 19: Parenteral Nutrition Market, Global, Product Profile - ClinOleic 20%, 2012 34Figure 20: Parenteral Nutrition Market, Global, Product Profile - Clinisol 15%, 2012 35Figure 21: Parenteral Nutrition Market, Global, Product Profile - NuTRIflex, 2012 36Figure 22: Parenteral Nutrition Market, Global, Product Profile - Lipofundin, 2012 37Figure 23: Parenteral Nutrition Market, Global, Product Profile - Aminoplasmal, 2012 38Figure 24: Parenteral Nutrition Market, Global, Product Profile - FreAmine III, 2012 39Figure 25: Parenteral Nutrition Market, Global, Product Profile-Intralipid, 2012 40Figure 26: Parenteral Nutrition Market, Global, Product Profile - SmofKabiven, 2012 41Figure 27: Parenteral Nutrition Market, Global, Product Profile - Dipeptiven, 2012 42Figure 28: Parenteral Nutrition Market, Global, Product Profile - Omegaven, 2012 43Figure 29: Parenteral Nutrition Market, Global, Product Profile - Aminosyn, 2012 44Figure 30: Parenteral Nutrition Market, Global, Product Profile - Liposyn, 2012 46Figure 31: Parenteral Nutrition Market, Global, Product Profile - Neoparen, 2012 47Figure 32: Parenteral Nutrition Market, Global, Product Profile - B-Fluid, 2012 48Figure 33: Parenteral Nutrition Market, Global, Product Profile - Unicaliq, 2012 49Figure 34: Parenteral Nutrition Market, Global, Product Profile - Fulcaliq, 2012 50Figure 35: Parenteral Nutrition Market, Global, Market Share of Top Manufacturers (%), 2011 51Figure 36: Parenteral Nutrition Market to 2018, Global, Company Profile - Baxter International Inc., 2012 52Figure 37: Parenteral Nutrition Market, Global, SWOT Analysis - Baxter International Inc., 2012 53Figure 38: Parenteral Nutrition Market to 2018, Global, Company Profile - B. Braun Melsungen AG, 2012 54Figure 39: Parenteral Nutrition Market, Global, SWOT Analysis - B. Braun Melsungen AG, 2012 55Figure 40: Parenteral Nutrition Market, Global, Company Profile - Fresenius Kabi AG, 2012 56Figure 41: Parenteral Nutrition Market, Global, SWOT Analysis - Fresenius Kabi AG, 2012 57Figure 42: Parenteral Nutrition Market, Global, Company Profile - Hospira Inc., 2012 58Figure 43: Parenteral Nutrition Market, Global, SWOT Analysis - Hospira Inc., 2012 59Figure 44: Parenteral Nutrition Market, Global, Company Profile - Otsuka Pharmaceutical Factory Inc., 2012 60Figure 45: Parenteral Nutrition Market, Global, Company Profile - Terumo Corporation, 2012 61Figure 46: Parenteral Nutrition Market, Global, Strategic Consolidations Overview (%), 2012 62

Companies mentioned

Baxter International Inc.

B. Braun Melsungen AG

Fresenius Kabi AG

Hospira, Inc.

Otsuka Pharmaceutical Factory Inc.

Terumo Corporation

To order this report:Pharmaceutical Industry: Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth

Nicolas Bombourg
Reportlinker
Email:
[email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discussed how a new approach is neces...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...